T2D patients who are candidates for basal insulin are those whose glycemic control targets cannot be achieved with oral hypoglycemic drugs, and, therefore, they require the introduction of insulin therapy either as an adjuvant or switching treatment strategy [42]. The gene discussed is INS; the disease is type 2 diabetes mellitus.